logo-loader
viewSynairgen PLC

Synairgen rockets as trial results could signal "major breakthrough" in treatment of severely ill COVID-19 patients

People who received SNG001, an inhaled formulation of interferon beta, had a 79% lower risk of developing the severe disease compared to those given the placebo, the data revealed

Synairgen PLC -

Synairgen PLC (LON:SNG) chief executive Richard Marsden said positive results from a clinical trial of its drug to tackle the severe symptoms of coronavirus (COVID-19) “could signal a major breakthrough in the treatment of hospitalised patients”.

People who received SNG001, an inhaled formulation of interferon beta, had a 79% lower risk of developing severe disease compared to those given the placebo, the data revealed.

They were also more than twice as likely to recover from the illness than those receiving the substance with no therapeutic value.

“Our efforts are now focused on working with the regulators and other key groups to progress this potential COVID-19 treatment as rapidly as possible,” Marsden said in a statement.

A total of 101 people took part in the clinical assessment at nine sites between March 30 and May 27.

Trial chief delighted

It was a double-blind, placebo-controlled study, which meant one group received SNG001, and the others did not.

Trial chief investigator, Professor Tom Wilkinson, said he was “delighted” by the results produced and hailed the “momentous coordinated effort” from Synairgen, the University of Southampton and University Hospital Southampton NHS Foundation Trust, which collaborated on the research.

"The results confirm our belief that interferon beta, a widely known drug that, by injection, has been approved for use in a number of other indications, has huge potential as an inhaled drug to be able to restore the lung’s immune response, enhancing protection, accelerating recovery and countering the impact of SARS-CoV-2 virus,” he added. 

Synairgen shares skyrocketed 541% to 230.6p by lunchtime on Monday.

finnCap bullish 

Mark Brewer, analyst at broker finnCap, increased his price target to 360p, which implies 886% ‘upside’ from Friday’s close of 36.5p.

He added that quantifying the coronavirus opportunity was “nigh on impossible” as he admitted the valuation “could go substantially higher”.

What happens next will depend on the “upcoming discussions with regulators, which should clarify the route to market and the potential for buying SNG001 ahead of the winter 2020 flu season and the possibility of a second wave of COVID-19”.

---adds analyst comment---

Quick facts: Synairgen PLC

Price: 220 GBX

AIM:SNG
Market: AIM
Market Cap: £328.75 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC's Richard Marsden hails positive results from study on...

Synairgen PLC's (LON:SNG) chief executive Richard Marsden speaks to Proactive London's Andrew Scott soon after announcing positive results from the clinical trial of its drug to tackle the severe symptoms of coronavirus (COVID-19). He says the study could signal a major breakthrough in the...

3 weeks, 1 day ago

2 min read